The CHRYSALIS-2 study (NCT04077463) evaluated the combination of amivantamab (Rybrevant), an EGFR-MET bispecific antibody, ...

We are working with Guy’s and St. Thomas’ NHS Foundation Trust to produce national standardised SACT regimen-specific consent forms. We want to support clinicians in ensuring all patients are fully ...

The study also revealed that patients with these mutations are predominantly treated with chemotherapy, even when their mutations fall under the afatinib label, with an average real-world duration of ...

Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have ...